Journal
EXPERIMENTAL NEUROLOGY
Volume 285, Issue -, Pages 12-23Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2016.08.012
Keywords
Huntington's disease; Glatiramer acetate; BDNF; Astrocytes; Neuroprotection
Categories
Funding
- TEVA
- Biogenldec
- TEVA Pharma
- Novartis Pharma
- Merck Serono
- Baxter
- Bayer Healthcare
- Merck-Serono
- Roche
- Genzyme
- Sanofi-Aventis
- Teva Pharma GmbH
- Biogen
- 'Cure Huntington's Disease Initiative' (CHDI)
- Biogen Idec
- Novartis Foundation
Ask authors/readers for more resources
Glatiramer acetate (GA) is a FDA-approved drug which is licensed for the treatment of relapsing-remitting multiple sclerosis and which may exert neuroprotective effects via brain-derived neurotrophic factor (BDNF). In this study, we investigate effects of GA on BDNF expression especially in astrocytes in vitro and in vivo in brains of R6/2 and YAC128 transgenic mouse models of Huntington's disease (HD) where a pathogenic role of astroglial cells has recently been shown. We show that GA increases the expression of functionally active BDNF in astrocyte culture and in astrocytes of GA treated HD mice. In the brains of these mice, GA decreases neurodegeneration and restores BDNF levels. The beneficial effect of GA in R6/2 mice also comprises reduced weight loss and prolonged life span and, for both models, also improved motor performance. Further studies with this safe and effective drug in HD are warranted. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available